Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07118085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women

Name: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women — clinical trial record (NCT07118085)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Started2025-08-18

View on ClinicalTrials.gov ↗

Amendment history

2025-12-07

Not Yet Recruiting→Recruiting Study Status, Arms and Interventions, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

2025-08-11

Original filing

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

10 trials monitored

See all monitored trials

this study is a randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMC-003 for injection in healthy postmenopausal women.

Trial Details

NCT Number	NCT07118085
Lead Sponsor	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions	Healthy Postmenopausal Women
Enrollment	56 participants
Start Date	2025-08-18
Primary Completion	2027-05-20 (estimated)
Study Completion	2027-08-20 (estimated)
Updated on ClinicalTrials.gov	2025-12-15